Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, ...

A new report from OKRs Tool reveals what actually drives OKR success inside fast-moving startups. Based on responses from over 200 early- and growth-stage companies, the 2026 OKR Benchmark Report ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial ...

Shutterstock, Inc. (the "Company"), a family of brands delivering scalable creative and GenAI solutions to help customers fuel great work, today announced financial results for the third quarter ended ...

The company expects to share safety and efficacy results from the RAMP-205 expansion cohort in first-line advanced pancreatic cancer and initial results from the Phase I/IIa trial evaluating VS-7375 ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...

New research from Moffitt Cancer Center shows that RAS(ON) multi-selective inhibition can directly block tumor growth and ...

Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic ...

Joshua K. Sabari, MD, director of High Reliability Organization Initiatives at NYU Langone Health's Perlmutter Cancer Center, ...

This study provides fundamental information on how Arg-II participates in cardiac aging. The phenotypic data provide convincing evidence of non-cell-autonomous contributions to aging-related ...

Parkinson's and Alzheimer's diseases are the two most common neurodegenerative disorders, affecting millions of people worldwide.